Tudorza Pressair 400 mcg/INHAL Dry Powder Inhaler, 30 ACTUAT
RxNorm 1607112
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1607112 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Tudorza Pressair 400 mcg/INHAL Dry Powder Inhaler, 30 ACTUAT.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
30 ACTUAT aclidinium bromide 0.4 mg/ACTUAT Dry Powder Inhaler [Tudorza]
(Atom ID: 6838527)
SYPrescribable
Synonym (SY):
30 ACTUAT Tudorza 0.4 mg/ACTUAT Dry Powder Inhaler
(Atom ID: 6838528)
SYPrescribable
Synonym (SY):
Tudorza Pressair 400 mcg/ACTUAT Dry Powder Inhaler, 30 ACTUAT
(Atom ID: 7706401)
PSNPrescribable
Prescribable Name (PSN):
Tudorza Pressair 400 mcg/INHAL Dry Powder Inhaler, 30 ACTUAT
(Atom ID: 6838532)
Patient Education
Aclidinium Oral Inhalation
Aclidinium is used as a long term treatment to prevent wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD, a group of diseases that affect the lungs and airways) such as chronic bronchitis (swelling of the air passages that lead to the lungs) and emphysema (damage to air sacs in the lungs). Aclidinium is in a class of medications called bronchodilators. It works by relaxing and opening the air passages to the lungs to make breathing easier.
[Learn More]
* Please review the disclaimer below.